These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 33451979)
21. Gene expression network analysis of ETV1 reveals KCTD10 as a novel prognostic biomarker in gastrointestinal stromal tumor. Kubota D; Yoshida A; Tsuda H; Suehara Y; Okubo T; Saito T; Orita H; Sato K; Taguchi T; Yao T; Kaneko K; Katai H; Kawai A; Kondo T PLoS One; 2013; 8(8):e73896. PubMed ID: 23977394 [TBL] [Abstract][Full Text] [Related]
22. Survivin is a novel transcription regulator of KIT and is downregulated by miRNA-494 in gastrointestinal stromal tumors. Yun S; Kim WK; Kwon Y; Jang M; Bauer S; Kim H Int J Cancer; 2018 May; 142(10):2080-2093. PubMed ID: 29277888 [TBL] [Abstract][Full Text] [Related]
23. Gastrointestinal stromal tumors (GIST): a single center experience. Kostka R; Gürlich R; Koldová L Acta Chir Belg; 2012 Jan; 112(1):33-9. PubMed ID: 22442907 [TBL] [Abstract][Full Text] [Related]
24. CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers. Chen J; Guo T; Zhang L; Qin LX; Singer S; Maki RG; Taguchi T; Dematteo R; Besmer P; Antonescu CR Genes Chromosomes Cancer; 2012 Feb; 51(2):186-95. PubMed ID: 22076958 [TBL] [Abstract][Full Text] [Related]
25. Anti-tumor effects of the Notch pathway in gastrointestinal stromal tumors. Dumont AG; Yang Y; Reynoso D; Katz D; Trent JC; Hughes DP Carcinogenesis; 2012 Sep; 33(9):1674-83. PubMed ID: 22764137 [TBL] [Abstract][Full Text] [Related]
26. Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA. Beadling C; Patterson J; Justusson E; Nelson D; Pantaleo MA; Hornick JL; Chacón M; Corless CL; Heinrich MC Cancer Med; 2013 Feb; 2(1):21-31. PubMed ID: 24133624 [TBL] [Abstract][Full Text] [Related]
27. Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors. Hsueh YS; Chang HH; Shan YS; Sun HS; Fletcher JA; Li CF; Chen LT Oncogene; 2019 Sep; 38(38):6550-6565. PubMed ID: 31363162 [TBL] [Abstract][Full Text] [Related]
28. High expression of the RNA-binding protein RBPMS2 in gastrointestinal stromal tumors. Hapkova I; Skarda J; Rouleau C; Thys A; Notarnicola C; Janikova M; Bernex F; Rypka M; Vanderwinden JM; Faure S; Vesely J; de Santa Barbara P Exp Mol Pathol; 2013 Apr; 94(2):314-21. PubMed ID: 23295309 [TBL] [Abstract][Full Text] [Related]
29. Gastrointestinal stromal tumor: an ultrastructural investigation on regional differences with considerations on their histogenesis. Min KW Ultrastruct Pathol; 2010 May; 34(3):174-88. PubMed ID: 20455665 [TBL] [Abstract][Full Text] [Related]
30. Gastrointestinal stromal tumor of unusual phenotype after imatinib treatment: A case report and diagnostic utility of ETV1 mRNA in situ hybridization. Jung M; Park SH; Jeon YK; Won JK; Yang HK; Kim WH Medicine (Baltimore); 2017 Dec; 96(49):e9031. PubMed ID: 29245294 [TBL] [Abstract][Full Text] [Related]
31. Prevalence and significance of M541L single nucleotide polymorphism in the central European cohort of gastrointestinal stromal tumor patients. Jasek K; Grendar M; Stanclova A; Malicherova B; Kasubova I; Burjanivova T; Szepe P; Ciccocioppo R; Rodrigo L; Prosecky R; Kruzliak P; Plank L; Lasabova Z J Cancer Res Clin Oncol; 2021 Apr; 147(4):1203-1215. PubMed ID: 33044628 [TBL] [Abstract][Full Text] [Related]
32. SLITRK3 expression correlation to gastrointestinal stromal tumor risk rating and prognosis. Wang CJ; Zhang ZZ; Xu J; Wang M; Zhao WY; Tu L; Zhuang C; Liu Q; Shen YY; Cao H; Zhang ZG World J Gastroenterol; 2015 Jul; 21(27):8398-407. PubMed ID: 26217092 [TBL] [Abstract][Full Text] [Related]
33. RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor. Gao X; Xue A; Fang Y; Shu P; Ling J; Hou Y; Shen K; Qin J; Sun Y; Qin X Oncotarget; 2016 Mar; 7(12):14300-9. PubMed ID: 26893362 [TBL] [Abstract][Full Text] [Related]
34. The V654A second-site KIT mutation increases tumor oncogenesis and STAT activation in a mouse model of gastrointestinal stromal tumor. Zhang JQ; Bosbach B; Loo JK; Vitiello GA; Zeng S; Seifert AM; Medina BD; Param NJ; Maltbaek JH; Rossi F; Antonescu CR; Besmer P; DeMatteo RP Oncogene; 2020 Dec; 39(49):7153-7165. PubMed ID: 33024275 [TBL] [Abstract][Full Text] [Related]
35. FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor. Ran L; Chen Y; Sher J; Wong EWP; Murphy D; Zhang JQ; Li D; Deniz K; Sirota I; Cao Z; Wang S; Guan Y; Shukla S; Li KY; Chramiec A; Xie Y; Zheng D; Koche RP; Antonescu CR; Chen Y; Chi P Cancer Discov; 2018 Feb; 8(2):234-251. PubMed ID: 29162563 [TBL] [Abstract][Full Text] [Related]
36. Stem cell factor-mediated wild-type KIT receptor activation is critical for gastrointestinal stromal tumor cell growth. Bai CG; Hou XW; Wang F; Qiu C; Zhu Y; Huang L; Zhao J; Xu JJ; Ma DL World J Gastroenterol; 2012 Jun; 18(23):2929-37. PubMed ID: 22736916 [TBL] [Abstract][Full Text] [Related]
37. Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. Bardsley MR; Horváth VJ; Asuzu DT; Lorincz A; Redelman D; Hayashi Y; Popko LN; Young DL; Lomberk GA; Urrutia RA; Farrugia G; Rubin BP; Ordog T Gastroenterology; 2010 Sep; 139(3):942-52. PubMed ID: 20621681 [TBL] [Abstract][Full Text] [Related]
38. The role of FBXW7, a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors. Koga Y; Iwatsuki M; Yamashita K; Kiyozumi Y; Kurashige J; Masuda T; Eto K; Iwagami S; Harada K; Ishimoto T; Baba Y; Yoshida N; Miyanari N; Takamori H; Ajani JA; Baba H Gastric Cancer; 2019 Nov; 22(6):1100-1108. PubMed ID: 30854619 [TBL] [Abstract][Full Text] [Related]
39. Oncogene mutational analysis in imatinib naive population of gastrointestinal stromal tumor patients. Ali Abuderman AW; M Aldakheel F Cell Mol Biol (Noisy-le-grand); 2020 Dec; 66(8):26-32. PubMed ID: 34174973 [TBL] [Abstract][Full Text] [Related]
40. Exon 11 homozygous mutations and intron 10/exon 11 junction deletions in the KIT gene are associated with poor prognosis of patients with gastrointestinal stromal tumors. Shen YY; Ma XL; Wang M; Zhuang C; Ni B; Tu L; Liu Q; Zhao WY; Cao H Cancer Med; 2020 Sep; 9(18):6485-6496. PubMed ID: 32697050 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]